While PD-1/PD-L1 inhibitors have shown considerable success in cancer treatment, their potential benefits for infectious diseases, such as HIV-1, hepatitis B or C virus patients, particularly, in improving T-cell function, are still being explored.2,13 However, deeper insights into PD-1 are needed to address potential treatment resistance. This evidence concerns the gene CD274 and infectious disease.